Kit for radiolabeling ligands with yttrium-90

Details Kit for radiolabeling ligands with yttrium-90 Kit for radiolabeling ligands with yttrium-90

2006-02-07

2006-02-07

Saunders, David (Department: 1644)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

C424S179100, C530S391500

Reexamination Certificate

active

06994840

ABSTRACT:
Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.

REFERENCES:
patent: 3994966 (1976-11-01), Sundberg et al.
patent: 4043998 (1977-08-01), Meares et al.
patent: 4315851 (1982-02-01), Yoshikumi et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4401592 (1983-08-01), Yoshikumi et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4460559 (1984-07-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4622420 (1986-11-01), Meares et al.
patent: 4634586 (1987-01-01), Goodwin et al.
patent: 4636380 (1987-01-01), Wong
patent: 4707352 (1987-11-01), Stavrianopoulos
patent: 4722892 (1988-02-01), Meares et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4767609 (1988-08-01), Stavrianpoulos
patent: 4816567 (1989-03-01), Cabilly
patent: 4824986 (1989-04-01), Gansow et al.
patent: 4831175 (1989-05-01), Gansow et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4861579 (1989-08-01), Meyer, Jr. et al.
patent: 4921690 (1990-05-01), Beatty et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5009069 (1991-04-01), Molini
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5059518 (1991-10-01), Kortright et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162115 (1992-11-01), Pietronigro
patent: 5208008 (1993-05-01), Ranadive et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5219556 (1993-06-01), Wolfangel
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5286850 (1994-02-01), Gansoh et al.
patent: 5363846 (1994-11-01), Rubin et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5403573 (1995-04-01), Day et al.
patent: 5428154 (1995-06-01), Gansow et al.
patent: 5434287 (1995-07-01), Gansow et al.
patent: 5460785 (1995-10-01), Rhodes
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5541287 (1996-07-01), Yau
patent: 5545403 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5620675 (1997-04-01), McBride et al.
patent: 5641637 (1997-06-01), Hudak et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5698178 (1997-12-01), Goldenberg
patent: 5728369 (1998-03-01), Griffiths
patent: 5766571 (1998-06-01), Ceriani et al.
patent: 5820845 (1998-10-01), Dean et al.
patent: 5830431 (1998-11-01), Srinivasan et al.
patent: 5942210 (1999-08-01), Ultee et al.
patent: 5976492 (1999-11-01), Griffiths et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 0 274 394 (1988-07-01), None
patent: 0 315188 (1989-05-01), None
patent: 0 315188 (1989-05-01), None
patent: 0 529 645 (1993-03-01), None
patent: WO 88/04936 (1988-07-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 94 11026 (1994-05-01), None
patent: WO96/14879 (1996-05-01), None
Kukis et al, “Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates”, J. Nucl. Med. 1998, 39:2105-2110.
Griffiths et al, “Rapid, facile and quantitative radiolabeling of DOTA-hMAb conjugates with Y-90 cancer radioimmunotherapy”, Abstract from AACR Meeting, No. 4242.
Pai-Scherf et al, “Imaging and phase I study of111In- and90Y-labeled anti-LewisYmonoclonal antibody”, Abstract from AACR Meeting No. 4240.
Kobayashi et al, Pharmacokinetics of In-111 and I-125 labeled anti-Tac single-chain Fv recombinant immunotoxin (LMB2), Abstract from AACR Meeting No. 4239.
Grossbard et al, “Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma”, Blood 80(4):863-876 (1992).
Applebaum, “Radiolabeled Monoclonal Antibodies in Treatment of NHL”, Hematology/ Oncology Clinics of North America 5(5):1013-1025 (1991).
Larson et al, “Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose . . . to Man”, Nucl. Med. Biol. 16(2):153-158 (1989).
Reilly, “Radioimmunotherapy of Malignancies”, Clin. Pharm. 10(5):359-375 (1991).
Stewart et al, “Intraperitoneal131I- and90Y-labeled Monoclonal Antibodies for Ovarian Cancer: Pharmocokinetics and . . . Dosimetry”, Int. J. Cancer Suppl. 3:71-76 (1988).
Kaminski et al, “131I Anti-B1: Initial Clinical Evaluation of B Cell Lymphoma”, Third Conference on Radioimmunodetection and . . . Cancer, Abstract No. 144, (1990).
Kaminski et al, “Initial Clinical Radioimmunotherapy Results with131I (Anti-CD20) in Refractory B Cell Lymphoma”, Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer Antibody . . . , 5(3) Abstract No. 57.
Nicholson et al, “Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced . . . analysis”, Oncology Reports, 5:223-226, 1998.
Hird et al, “Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody”, Br. J. Cancer, 68:403-406, 1993.
Richardson et al, “Optimization and batch production of DTPA-labelled antibody kits for routine use in111In immunoscintigraphy”, Nucl. Med. Communications, 8:347-356, 1987.
Chinol et al, “Generator-Produced Yttrium-90 for Radioimmunotherapy”, 28(9):1465-1470, 1987.
Kinsey et al, “Efficient Conjugation of DTPA to an IgM Monoclonal Antibody in Ascites Fluid”, Nucl. Med. Biol., 15(3):285-292, 1988.
Washburn et al, Preclinical Assessment of90Y-Labeled Monoclonal Antibody CO17-1A, a Potential Agent . . . Carcinoma, Nucl. Med. Biol., 15(6):707-711, 1988.
Motta-Hennessy et al, “Labeling of Monoclonal Antibody Conjugates with90Y”, Appl. Radiat. Isot., 42(5):421-426, 1991.
Mirzadeh et al, “The Chemical Fate of212Bi-DOTA Forbed by β- Decay of212Pb(DOTA)2”, Radiochimica Acta, 60(1):1-10, 1993.
Brechbiel et al, “Synthesis of C-Functionalized trans-Cyclohexyldiethylenetriaminepenta-acetic Acids for Labelling . . . Emitter”, J. Chem. Soc. Perkin Trans., 1173-1178, 1992.
Izard et al, “An Improved Method for Labelling Monoclonal Antibodies with Samarium-153: Use of the Bifunctional Chelate . . . Acid”, Bioconjugate Chem, 3(4), 346-350, 1992.
Huneke et al, “Effective α-Particle-mediated Radioimmunotherapy of Murine Leukimia”, Cancer Research, 52:5818-5820, 1992.
Gansow et al, “Macrocyclic or Conventional Ligands? Selection of Effective Chelators . . . Radioimmunotherapy”, Chem. Sect., Radiation Oncol. Branch, Natl. Canc. Inst.
Antisoma, Internet reference, 16 pp.
Cytogen, Internet reference, 15 pp.
Gansow et al., Advanced Methods for Radiolabeling Monoclonal Antibodies with Therapeutic Radionuclides,Cancer Therapy With Radiolabelled Antibodies, 1995, Chapter 6, pp. 63-76.
Gary L. Griffiths, Antibody Radiolabeling With Isotopes of Rhenium,Cancer Therapy With Radiolabelled Antibodies, 1995, Chapter 7, pp. 77-86.
Adams RA, “Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma,”Cancer Research, 1967, 27(1):2479-2482.
Adams RA, et al., “Direct implantation and transplantation of human acute lymphoblastic leukemia in hamsters, SB-2,” 1968,Cancer Research, 1968, 28:1121-1125.
Chakrabarti MC et al., “Prevention of radiolysis of monoclonal antibody during labeling,”J. Nucl. Med., 1996, 37(8):1384-88.
DeNardo et al., “Yttrium-90/Indium-111 DOTA peptide chimeric L6: pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer,” J. Nucl. Med., 1995, 36:97P.
Kozak RW, et al., “Nature of the bifunctional

Affiliated with

Also associated with

Rating

Kit for radiolabeling ligands with yttrium-90 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Kit for radiolabeling ligands with yttrium-90, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kit for radiolabeling ligands with yttrium-90 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3681405